Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.